{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:43Z","timestamp":1791335623256,"version":"4.3.1"},"reference-count":66,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PP00P3_159269"],"award-info":[{"award-number":["PP00P3_159269"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Polianthes Foundation","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite advances in malignant pleural mesothelioma therapy, life expectancy of affected patients remains short. The limited efficiency of treatment options is mainly caused by inter- and intra-tumor heterogeneity of mesotheliomas. This diversity can be observed at the morphological and molecular levels. Molecular analyses reveal a high heterogeneity (i) between patients; (ii) within different areas of a given tumor in terms of different clonal compositions; and (iii) during treatment over time. The aim of the present review is to highlight this diversity and its therapeutic implications.<\/jats:p>","DOI":"10.3390\/ijms19061603","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T03:04:27Z","timestamp":1527649467000},"page":"1603","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Heterogeneity in Malignant Pleural Mesothelioma"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5866-7068","authenticated-orcid":false,"given":"Kathrin","family":"Oehl","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, University Hospital Zurich, 8091 Z\u00fcrich, Switzerland"},{"name":"Institute of Pathology and Molecular Pathology, University Hospital Z\u00fcrich, 8091 Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6063-832X","authenticated-orcid":false,"given":"Bart","family":"Vrugt","sequence":"additional","affiliation":[{"name":"Institute of Pathology and Molecular Pathology, University Hospital Z\u00fcrich, 8091 Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Hospital Zurich, 8091 Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayura","family":"Meerang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Hospital Zurich, 8091 Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1440-1843.2005.00694.x","article-title":"Pathogenesis of malignant pleural mesothelioma","volume":"10","author":"Jaurand","year":"2005","journal-title":"Respirology"},{"key":"ref_2","first-page":"S238","article-title":"Management of malignant pleural mesothelioma-the european experience","volume":"6","author":"Opitz","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/JTO.0000000000000661","article-title":"A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: A review of 12 years\u2019 experience","volume":"10","author":"Opitz","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.lungcan.2015.06.018","article-title":"Second line therapy in malignant pleural mesothelioma: A systematic review","volume":"89","author":"Buikhuisen","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (maps): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jare.2014.11.012","article-title":"Mesothelioma treatment: Are we on target? A review","volume":"6","author":"Hiddinga","year":"2015","journal-title":"J. Adv. Res."},{"key":"ref_8","unstructured":"(2018, April 30). COSMIC database, w.s.i. Available online: Https:\/\/cancer.Sanger.Ac.Uk\/cosmic."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1078-0432.CCR-09-1660","article-title":"Somatic egfr mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer","volume":"16","author":"Dahabreh","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: A multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_11","first-page":"FV21","article-title":"Sarcomatoid differentiation during progression of malignant pleural mesothelioma","volume":"140","author":"Vrugt","year":"2015","journal-title":"Zent. Chir. Z. Allg. Vis. Thorac. Gef\u00e4\u00dfch."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: A looking glass for cancer?","volume":"12","author":"Marusyk","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in bap1, nf2, cdkn2a, and cul1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase bap1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/15384047.2016.1145850","article-title":"Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration","volume":"17","author":"Borczuk","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ijc.23949","article-title":"Genomic events associated with progression of pleural malignant mesothelioma","volume":"124","author":"Ivanov","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_18","first-page":"2108","article-title":"Homozygous deletion of cdkn2a and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: A retrospective study","volume":"10","author":"Monica","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00408-015-9814-7","article-title":"Driver gene and novel mutations in asbestos-exposed lung adenocarcinoma and malignant mesothelioma detected by exome sequencing","volume":"194","author":"Sarhadi","year":"2016","journal-title":"Lung"},{"key":"ref_21","first-page":"2331","article-title":"Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma","volume":"36","author":"Ugurluer","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic landscape of malignant mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2014.08.004","article-title":"Identification of actionable mutations in malignant pleural mesothelioma","volume":"86","author":"Shukuya","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"Egfr overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1440-1827.2011.02778.x","article-title":"A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma","volume":"62","author":"Enomoto","year":"2012","journal-title":"Pathol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1535-6108(04)00122-9","article-title":"Predictive factors for epidermal growth factor receptor inhibitors\u2014The bull\u2019s-eye hits the arrow","volume":"5","author":"Dancey","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase ii study of erlotinib in patients with malignant pleural mesothelioma: A southwest oncology group study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: A phase II study by the cancer and leukemia group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e20030","DOI":"10.1200\/JCO.2017.35.15_suppl.e20030","article-title":"Cetuximab plus platinum-based chemotherapy in patients with malignant pleural mesothelioma: A single arm phase ii trial","volume":"35","author":"Paepe","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5858\/arpa.2015-0508-LE","article-title":"Immunohistochemistry for nf2, lats1\/2, and yap\/taz fails to separate benign from malignant mesothelial proliferations","volume":"140","author":"Sheffield","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jtho.2016.05.020","article-title":"The genetic landscape of malignant pleural mesothelioma: Results from massively parallel sequencing","volume":"11","author":"Hylebos","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_33","first-page":"2589","article-title":"Status of anaplastic lymphoma kinase (alk) in malignant mesothelioma","volume":"34","author":"Varesano","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20781","DOI":"10.18632\/oncotarget.25111","article-title":"A subgroup of pleural mesothelioma expresses alk protein and may be targetable by combined rapamycin and crizotinib therapy","volume":"9","author":"Kalla","year":"2018","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anndiagpath.2016.04.007","article-title":"C-met expression and met amplification in malignant pleural mesothelioma","volume":"23","author":"Bois","year":"2016","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.athoracsur.2009.09.028","article-title":"Second surgery for recurrence of malignant pleural mesothelioma after extrapleural pneumonectomy","volume":"89","author":"Politi","year":"2010","journal-title":"Ann. Thorac. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jtcvs.2014.10.128","article-title":"Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma","volume":"149","author":"Baldini","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nature14971","article-title":"A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity","volume":"525","author":"Waclaw","year":"2015","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1309\/AJCPT94JVWIHBKRD","article-title":"Diagnostic usefulness of p16\/cdkn2a fish in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis","volume":"139","author":"Wu","year":"2013","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1278330","DOI":"10.1080\/2162402X.2016.1278330","article-title":"Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma","volume":"6","author":"Kiyotani","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"i90","DOI":"10.1093\/jrr\/rrw007","article-title":"The impact of hypoxia and its modification of the outcome of radiotherapy","volume":"57","author":"Horsman","year":"2016","journal-title":"J. Radiat. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2015.07.015","article-title":"Characterization of hypoxia in malignant pleural mesothelioma with fmiso pet-ct","volume":"90","author":"Francis","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e1356146","DOI":"10.1080\/2162402X.2017.1356146","article-title":"Temporal and spatial heterogeneity of programmed cell death 1-ligand 1 expression in malignant mesothelioma","volume":"6","author":"Terra","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and therapeutic impact of intratumor heterogeneity in cancer evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature16478","article-title":"Divergent clonal selection dominates medulloblastoma at recurrence","volume":"529","author":"Morrissy","year":"2016","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.celrep.2013.12.041","article-title":"Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity","volume":"6","author":"Almendro","year":"2014","journal-title":"Cell Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fonc.2018.00040","article-title":"Live-cell mesothelioma biobank to explore mechanisms of tumor progression","volume":"8","author":"Oehl","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JTO.0000000000000055","article-title":"Pi3k\/mtor signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy","volume":"9","author":"Bitanihirwe","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.molonc.2016.06.005","article-title":"Low merlin expression and high survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma","volume":"10","author":"Meerang","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejca.2010.09.044","article-title":"Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis","volume":"47","author":"Sidi","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2010.04.020","article-title":"Characterization of side population cells in human malignant mesothelioma cell lines","volume":"70","author":"Kai","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/carcin\/bgr127","article-title":"Pleural mesothelioma side populations have a precursor phenotype","volume":"32","author":"Frei","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.7150\/jca.15423","article-title":"An integrated analysis of the genome-wide profiles of DNA methylation and mrna expression defining the side population of a human malignant mesothelioma cell line","volume":"7","author":"Kim","year":"2016","journal-title":"J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"237ra268","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts fak inhibitor sensitivity: A synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e1304","DOI":"10.1038\/cddis.2014.271","article-title":"Egf-induced adipose tissue mesothelial cells undergo functional vascular smooth muscle differentiation","volume":"5","author":"Lachaud","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"E748","DOI":"10.1073\/pnas.1320956111","article-title":"Mapping the molecular determinants of braf oncogene dependence in human lung cancer","volume":"111","author":"Lin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"69162","DOI":"10.18632\/oncotarget.19942","article-title":"Non-blood circulating tumor DNA detection in cancer","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Tie, J., Cohen, J.D., Wang, Y., Li, L., Christie, M., Simons, K., Elsaleh, H., Kosmider, S., Wong, R., and Yip, D. (2018). Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: A prospective biomarker study. Gut.","DOI":"10.1136\/gutjnl-2017-315852"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"346ra392","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage ii colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","article-title":"Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types","volume":"7","author":"Shu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrg.2017.117","article-title":"Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations","volume":"19","author":"Salk","year":"2018","journal-title":"Nat. Rev. Genet."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/6\/1603\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:06:28Z","timestamp":1760195188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/6\/1603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":66,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["ijms19061603"],"URL":"https:\/\/doi.org\/10.3390\/ijms19061603","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,30]]}}}